{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:01:59Z","timestamp":1788498119768,"version":"build-2803163510"},"reference-count":56,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":46,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Digest Diseases"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:p>Increasing antibiotic resistance is the primary reason for treatment failure of <jats:italic>Helicobacter pylori<\/jats:italic> (<jats:italic>H. pylori<\/jats:italic>) infection. To enhance the eradication rate, minimize the development of secondary resistance, and alleviate the socioeconomic burden, it is crucial to select <jats:italic>H. pylori<\/jats:italic>\u2010sensitive antibiotics carefully. Furazolidone has been used for <jats:italic>H. pylori<\/jats:italic> eradication in developing countries for decades due to its affordability and low resistance rate. Numerous studies have demonstrated that furazolidone\u2010containing regimens are more efficacious than those containing other antibiotics, as both first\u2010 and second\u2010line therapies, and are also well tolerated. However, utility of furazolidone is restricted or not optimal in certain countries due to its infrequent but potentially severe adverse effects. The decision to discontinue usage of furazolidone because of concerns regarding adverse effects may be misguided. Here we comprehensively reviewed the studies on furazolidone at different dosages and treatment durations for <jats:italic>H. pylori<\/jats:italic> eradication. Further research on the mechanisms of action and clinical trials of furazolidone are of great practical importance.<\/jats:p>","DOI":"10.1111\/1751-2980.13265","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T12:19:38Z","timestamp":1713269978000},"page":"148-155","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Application of furazolidone in <i>Helicobacter pylori<\/i> infection eradication"],"prefix":"10.1111","volume":"25","author":[{"given":"Ying Ying","family":"Han","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan Hubei Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Yan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan Hubei Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia Lun","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan Hubei Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan Hubei Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6300-1460","authenticated-orcid":false,"given":"Pei Yuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan Hubei Province China"},{"name":"Department of Gastroenterology Wenchang People's Hospital  Wenchang Hainan Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4,16]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00070-5"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.04.022"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312288"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30753-3"},{"issue":"22","key":"e_1_2_11_6_1","first-page":"1631","article-title":"Personalized therapy for Helicobacter pylori on initial treatment: the initial treatment is the decisive battle","volume":"102","author":"Gao HJ","year":"2022","journal-title":"Natl Med J China"},{"issue":"10","key":"e_1_2_11_7_1","first-page":"5027","article-title":"A retrospective study of the antibiotic\u2010resistant phenotypes and genotypes of Helicobacter pylori strains in China","volume":"11","author":"Zhong ZS","year":"2021","journal-title":"Am J Cancer Res"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.11.010"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12496"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.01.008"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12475"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0027-5107(90)90124-M"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006333608012"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.30.5.679"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1992.tb01034.x"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)92639-5"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00709.x"},{"issue":"3","key":"e_1_2_11_18_1","first-page":"233","article-title":"In vivo susceptibility of Campylobacter pylori","volume":"84","author":"Graham DY","year":"1989","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.7.2116-2123.2002"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens11070786"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.5662\/wjm.v5.i3.164"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2020.0088"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i37.6920"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00492.x"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00487.x"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01822.x"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v10.i5.747"},{"issue":"8","key":"e_1_2_11_28_1","first-page":"480","article-title":"Therapeutic effect of clarithromycin\u2010based triple therapy for Helicobacter pylori eradication","volume":"17","author":"Zhang QF","year":"2012","journal-title":"Chin J Gastroenterol"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2003.03058.x"},{"issue":"4","key":"e_1_2_11_30_1","first-page":"195","article-title":"A comparison between moderate\u2010 and high\u2010dose furazolidone in triple regimens for Helicobacter pylori eradication in Iran","volume":"6","author":"Hosseini V","year":"2014","journal-title":"Middle East J Dig Dis"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-28032005000200009"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12468"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-311019"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1159\/000048865"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12940"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.860"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00640.x"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00709.x"},{"key":"e_1_2_11_39_1","first-page":"195","article-title":"Comparison of quadruple and triple furazolidone containing regimens on eradication of Helicobacter pylori","volume":"29","author":"Mokhtare M","year":"2015","journal-title":"Med J Islam Repub Iran"},{"issue":"4","key":"e_1_2_11_40_1","first-page":"CR193","article-title":"Eradication rate of Helicobacter pylori in dyspeptic patients","volume":"11","author":"Amini M","year":"2005","journal-title":"Med Sci Monit"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.00166.x"},{"issue":"11","key":"e_1_2_11_42_1","first-page":"1218","article-title":"A study on the curative effect of modified seven\u2010day dual therapy in the primary treatment of Helicobacter pylori infection","volume":"24","author":"Wei LQ","year":"2019","journal-title":"Mod Dig Interv"},{"issue":"8","key":"e_1_2_11_43_1","first-page":"1173","article-title":"Clinical observation of modified dual therapy in the treatment of Helicobacter pylori infection","volume":"33","author":"Tang JF","year":"2022","journal-title":"Mod Diagn Treat"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12876"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.2302\/kjm.51.supplement2_33"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102020\u2010037375"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.4103\/1319-3767.91724"},{"issue":"9","key":"e_1_2_11_48_1","first-page":"639","article-title":"Applying furazolidone in standard to eradicate Helicobacter pylori","volume":"41","author":"Hu Y","year":"2021","journal-title":"Chin J Dig"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.192757"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327745"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002546"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn051"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i40.4596"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12143"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12692"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15917"},{"key":"e_1_2_11_57_1","first-page":"1","article-title":"Some food additives, feed additives and naturally occurring substances","volume":"31","author":"International Agency for Research on Cancer","year":"1983","journal-title":"IARC Monogr Eval Carcinog Risk Chem Hum"}],"container-title":["Journal of Digestive Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1751-2980.13265","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T02:01:13Z","timestamp":1714701673000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1751-2980.13265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1111\/1751-2980.13265"],"URL":"https:\/\/doi.org\/10.1111\/1751-2980.13265","archive":["Portico"],"relation":{},"ISSN":["1751-2972","1751-2980"],"issn-type":[{"value":"1751-2972","type":"print"},{"value":"1751-2980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"2023-06-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}